Caulley Lisa, Lasso Andrea, Zagorski Brandon, Wilton Andrew S, Saskin Refik, Sahlollbey Nick, Séguin Jeanne M, Thavorn Kednapa, Doyle Mary-Anne, Malcolm Janine, Alkherayf Fahad, Johnson-Obaseki Stephanie, Schramm David, Kilty Shaun
Department of Otolaryngology-Head and Neck Surgery, University of Ottawa, Ottawa, ON, Canada.
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands.
J Otolaryngol Head Neck Surg. 2025 Jan-Dec;54:19160216251314793. doi: 10.1177/19160216251314793.
Pituitary adenomas (PAs) present a notable economic burden on healthcare systems due to their management's reliance on multimodal, often costly interventions.
To determine total and relative healthcare costs for PAs at Ontario-based institutions.
A retrospective, propensity-score-matched cohort analysis.
Ontario, Canada, encompassing public healthcare facilities and covering costs over a 6-year study period.
Adults diagnosed with PA (n = 1675) between April 1, 2013, and March 31, 2019, compared to a general population cohort and a hospitalized control cohort matched on demographics and health factors.
INTERVENTION/EXPOSURES: Analysis of healthcare cost components (inpatient, outpatient, and diagnostic services) and cost trajectories postsurgery for PAs.
Primary outcome was total annualized healthcare costs for patients with PA relative to the general and hospitalized cohorts. Relative costs were estimated using a negative binomial regression model.
Of 1675 patients with PA, total annualized costs were $49,992. Highest total costs were associated with inpatient hospitalization ($24,796) and physician services/diagnostic evaluations ($20,075). After propensity score matching, patients with PA had 12.7 times higher costs [95% confidence interval (CI) (10.9, 14.8), < .0001] during the preadmission/admission period, which remained elevated postoperatively ( < .05). Total costs did not differ between patients with PA and the hospitalized cohort [RR 0.97, 95% CI (0.92, 1.03); = .3271] in the preadmission/admission period; however, follow-up costs were 37% lower for patients with PA in the 1st follow-up year [RR 0.63, 95% CI (0.51, 0.77); < .0001], and up to 50% lower by the 5th year [RR 0.50, 95% CI (0.36, 0.68); < .0001].
This study provided a comprehensive assessment of the economic burden of PAs on the publicly-funded healthcare system. Patients with PA had higher annualized total costs across all observed time periods compared to the general population and lower annualized total costs compared to patients admitted to a surgical ward.
This study highlights the financial impact of PA management on healthcare resources and provides a basis for future research aimed at cost-efficiency improvements in long-term PA care.
垂体腺瘤(PAs)因其管理依赖多模式且通常成本高昂的干预措施,给医疗保健系统带来了显著的经济负担。
确定安大略省各机构中垂体腺瘤的总医疗成本和相对医疗成本。
一项回顾性、倾向评分匹配队列分析。
加拿大安大略省,涵盖公共医疗设施,并涵盖6年研究期内的成本。
2013年4月1日至2019年3月31日期间被诊断为垂体腺瘤的成年人(n = 1675),与根据人口统计学和健康因素匹配的普通人群队列和住院对照队列进行比较。
干预措施/暴露因素:分析垂体腺瘤的医疗成本组成部分(住院、门诊和诊断服务)以及手术后的成本轨迹。
主要结局是垂体腺瘤患者相对于普通人群和住院队列的年度总医疗成本。使用负二项回归模型估计相对成本。
在1675例垂体腺瘤患者中,年度总成本为49,992美元。最高总成本与住院治疗(24,796美元)和医生服务/诊断评估(20,075美元)相关。倾向评分匹配后,垂体腺瘤患者在入院前/入院期间的成本高出12.7倍[95%置信区间(CI)(10.9,14.8),P <.0001],术后仍居高不下(P <.05)。在入院前/入院期间,垂体腺瘤患者与住院队列的总成本无差异[相对风险(RR)0.97,95% CI(0.92,1.03);P =.3271];然而,在第一次随访年中,垂体腺瘤患者的随访成本低37%[RR 0.63,95% CI(0.51,0.77);P <.0001],到第5年降低多达50%[RR 0.50,95% CI(0.36,0.68);P <.0001]。
本研究全面评估了垂体腺瘤对公共资助医疗系统的经济负担。与普通人群相比,垂体腺瘤患者在所有观察时间段内的年度总成本更高,与手术病房住院患者相比年度总成本更低。
本研究强调了垂体腺瘤管理对医疗资源的财务影响,并为未来旨在提高垂体腺瘤长期护理成本效益的研究提供了基础。